- Home
- IVVD vs CURR Comparison
IVVD vs CURR Comparison
Compare IVVD & CURR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- CURR
- Stock Information
- Founded
- IVVD 2020
- CURR 2013
- Country
- IVVD United States
- CURR Singapore
- Employees
- IVVD N/A
- CURR N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- CURR Business Services
- Sector
- IVVD Health Care
- CURR Consumer Discretionary
- Exchange
- IVVD Nasdaq
- CURR Nasdaq
- Market Cap
- IVVD 69.0M
- CURR 74.0M
- IPO Year
- IVVD 2021
- CURR N/A
- Fundamental
- Price
- IVVD $0.74
- CURR $1.59
- Analyst Decision
- IVVD Strong Buy
- CURR Strong Buy
- Analyst Count
- IVVD 3
- CURR 1
- Target Price
- IVVD $5.85
- CURR $3.50
- AVG Volume (30 Days)
- IVVD 1.3M
- CURR 10.5M
- Earning Date
- IVVD 08-13-2025
- CURR 08-11-2025
- Dividend Yield
- IVVD N/A
- CURR N/A
- EPS Growth
- IVVD N/A
- CURR N/A
- EPS
- IVVD N/A
- CURR N/A
- Revenue
- IVVD $36,688,000.00
- CURR $43,386,858.00
- Revenue This Year
- IVVD $446.60
- CURR N/A
- Revenue Next Year
- IVVD $112.63
- CURR $21.53
- P/E Ratio
- IVVD N/A
- CURR N/A
- Revenue Growth
- IVVD N/A
- CURR N/A
- 52 Week Low
- IVVD $0.35
- CURR $0.33
- 52 Week High
- IVVD $2.74
- CURR $7.08
- Technical
- Relative Strength Index (RSI)
- IVVD 48.03
- CURR N/A
- Support Level
- IVVD $0.70
- CURR N/A
- Resistance Level
- IVVD $0.77
- CURR N/A
- Average True Range (ATR)
- IVVD 0.05
- CURR 0.00
- MACD
- IVVD -0.00
- CURR 0.00
- Stochastic Oscillator
- IVVD 45.94
- CURR 0.00
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.